<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28427">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01910116</url>
  </required_header>
  <id_info>
    <org_study_id>GC6102F</org_study_id>
    <nct_id>NCT01910116</nct_id>
  </id_info>
  <brief_title>Efficacy of Shinabro in Hand OA</brief_title>
  <official_title>Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shibaro is a mixture of 6 oriental herbs that have anti-inflammatory and analgesic effects
      along with an excellent safety profile. This study is aimed at investigating efficacy of
      Shinbaro in the treatment of hand osteoarthritis which needs a long term treatment in a
      placebo controlled, double-blind randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA) as a common musculoskeletal disease affects more than 30% of the elderly
      population. It frequently involves knees, hips, spines and hands. In hands, the distal and
      proximal interphalangeal and the first carpometacarpal joints are affected, leading often to
      significant disability and limitation in the daily activity. The chronic progressive nature
      of the disease requires a life-long treatment. The mainstay treatment of hand OA targets
      pain control. Non-steroidal anti-inflammatory drugs (NSAIDs) are often used. However, they
      are frequently associated with significant gastrointestinal side effects including
      gastritis, peptic ulcer diseases, and bleeding, especially with long term use. Further, they
      do not ameliorate pain completely, requiring additional medications such as acetaminophen or
      opioid-based analgesics.

      Shibaro is a mixture of purified oriental herbs consisting of Ledebouriellae Radix,
      Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, and Eucommiae
      Cortex. These herbs have been used for the treatment of diverse inflammatory conditions in
      Chines traditional medicine. All 6 herbs show an excellent safety profile and their
      anti-inflammatory and analgesic effects have been studied in both animals and humans. As
      such, given the excellent safety profile, anti-inflammatory and analgesic effects, Shinbaro
      might be ideal in the treatment of OA.

      This study will investigate the efficacy and safety of Shinbaro in the treatment of hand OA
      in a placebo-controlled, randomized, double-blind, multi-center trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUSCAN Pain VAS with Shinbaro</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUSCAN pain VAS on 0-100 scale after 4 weeks with Shinbaro</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUSCAN Pain VAS with Placebo</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUSCAN Pain on 1-100mm VAS scale after 4 weeks with placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUSCAN stiffness and function</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUSCAN stiffness and function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN pain, stiffness and function</measure>
    <time_frame>4, 12, 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUSCAN pain, stiffness, and function from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Hand Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 capsules, twice daily, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shinbaro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shinbaro</intervention_name>
    <arm_group_label>Shinbaro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 40 years or older

          -  Osteoarthritis according to ACR 1990 criteria

          -  Mean AUSCAN visual analog pain score (VAS) &gt; 30mm in the preceding 48 hours

          -  Patients who are will to participate

        Exclusion Criteria:

          -  Any prior surgery of hand joints

          -  Intra-articular injection of glucocorticosteroid or hyaluronic acid in the preceding
             3 months

          -  Pregnancy or active breast feeding

          -  Prior hypersensitivity reaction to herbal medications

          -  AST or ALT elevation &gt; 3 of upper normal limit

          -  GRF (MDRD) &lt; 30 mg/min/1.73m2

          -  Nephrotic syndrome, other signficant kidney disease

          -  Patients who seem not to tolerate the study at investigator's discretion

          -  Patients who refuse to participate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eun Bong Lee, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Kyun Park, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yun Jong Lee, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National Universty Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kichul Shin, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eun Bong Lee, MD PhD</last_name>
    <phone>82-2-2072-3944</phone>
    <email>leb7616@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin Kyun Park, MD</last_name>
    <phone>82-2-2072-4765</phone>
    <email>jinkyunpark@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National Univ. Bundang Hospital</name>
      <address>
        <city>Bundang</city>
        <state>Gyeonggi-do</state>
        <zip>463-870</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yun Jong Lee, MD PhD</last_name>
      <phone>+82-31-787-4051</phone>
      <email>leeyn35@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yun Jong Lee, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Bong Lee, MD PhD</last_name>
      <phone>82-2-2072-3944</phone>
      <email>leb7616@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Jin Kyun Park, MD</last_name>
      <phone>82-2-2072-4765</phone>
      <email>jinkyunpark@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eun Bong Lee, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kichul Shin, MD PhD</last_name>
      <phone>+82-2-870-3204</phone>
      <email>kideb1@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kichul Shin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 22, 2013</lastchanged_date>
  <firstreceived_date>July 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Eun Bong Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>hand</keyword>
  <keyword>Shinbaro</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
